Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics - Myriad Genetics (NASDAQ:MYGN)

SALT LAKE CITY, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced it has entered into a definitive agreement to acquire select

Related Keywords

Utah ,United States ,Glenn Farrell ,Paulj Diaz ,Matt Scalo ,Intermountain Health System ,Exchange Commission ,Genetics Inc ,Intermountain Precision Genomic ,Tumor Test ,Precise Liquid Test ,Precise Tumor Test ,Precise Tumor ,Precise Liquid ,Intermountain Healthcare ,Solid Tumor ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,